CSL shares down 5% after post-heart attack drug disappoints in late-stage test
CSL’s cholesterol efflux enhancer failed to prevent repeat cardiac events in a Phase III study that recruited patients who had a recent myocardial infarction, prompting …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
